跳至主要内容
临床试验/JPRN-UMIN000011315
JPRN-UMIN000011315已完成2 期

The Feasibility Study of Adjuvant nab-paclitaxel+Carboplatin in Patients with Resected Stage IB-IIIA Non-Small-Cell Lung Cance - The Feasibility Study of Adjuvant nab-paclitaxel+Carboplatin in Patients with Resected Stage IB-IIIA Non-Small-Cell Lung Cance

Hiroshima University0 个研究点目标入组 40 人开始时间: 2013年9月5日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Allergy for CBDCA/nab-paclitaxel 2) History of Severe drug allergies 3) Myocardial infarction within 6 months 4) Interstitial pneumonia or pulmonary fibrosis detectable on X ray 5)Severe concurrent disease (Ischemic heart disease requiring treatment,arrhythmia,cardiac infarction within 6months before enrollment,hepatic failure,hemorrhagic peptic ulcer,poorly controlled diabetes) 6) History of active double cancerwithin 5years prior to the study 7) HBV-positive patients 8) Patients who are pregnant,considering pregnancy oractaing 9) Other conditions not suitable forthis study

研究者

相似试验